The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Jet2 swings to loss; Hyve Group sees busiest quarter

Thu, 08th Jul 2021 11:38

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Jet2 PLC - Yeadon, England-based airline and package holiday operator - Swings to a pretax loss of GBP369.9 million in the year ended March 31 from a profit of GBP147.7 million a year prior. Revenue sinks to GBP395.4 million from GBP3.58 billion. Single sector passengers flown comes in at 1.3 million, falling sharply from 14.6 million the year before. "Extensive restrictions on international travel imposed by the UK Government, meant our aircraft fleet was fully grounded for approximately 29 weeks of the financial year and operated with a significantly reduced programme when flying was permitted," says company. Does not declare a final dividend, unchanged from last year, given "the ongoing impact of Covid-19". This leaves shareholder's pockets empty for the year, compared to a total payout of 3.0 pence a year ago. "Group performance for the financial year ending March 31, 2022 is very much dependent on the level of flying permitted for the remainder of summer 2021 and performance in the second half of the financial year, periods for which we still have limited visibility. Unsurprisingly given the continuing short-term uncertainty, customers are booking significantly closer to departure for summer 2021; and, although bookings to date for [this coming winter] are satisfactory, they have slowed more recently given the ongoing speculation around international travel," says company.

----------

Hyve Group PLC - London-based exhibitions and conferences organiser - Says the third quarter to end June "has been the group's busiest trading quarter since the Covid-19 pandemic began". Says 18 in-person events ran over the quarter, bringing the total number for the year to date to 28. The increased number of events reflects the continued momentum across the group's Eastern markets, primarily Russia, China, Turkey and Ukraine, company says. "[The third quarter] is traditionally a strong trading period for the group and it is extremely encouraging that Hyve has successfully run more events in the quarter than in the entirety of the first half. Many of the group's key markets in the East have been open for a number of months now and, combined with the continued pace of the vaccine rollout in our Western markets, this gives the group continued confidence when looking ahead to the final quarter of [the 2021 financial year] and beyond," CEO Mark Shashoua says.

----------

Fuller, Smith & Turner PLC - London-based pub and hotel company - Reports pretax loss of GBP57.8 million in the year to March 27, swinging from a profit of GBP8.4 million a year ago. Revenue plummets to GBP73.2 million from GBP316.0 million due to the enforced closure of social businesses throughout the year. "No full year dividend proposed in light of pandemic impact on trading performance, but intention to return to progressive dividend policy at the appropriate time," says company. Did not pay a final dividend a year prior. "The boom in staycations and desire to get back out with friends has led to strong trading in parts of our estate - particularly Cotswold Inns & Hotels and our rural pubs with rooms - and there is an incredibly busy season to come with numerous weddings and a high level of advance bookings," says Chief Executive Simon Emeny. Aims at "sustainable returns for the long term".

----------

Equals Group PLC - London-based payments and e-banking firm - Says revenue for the first half to June 30 is up 21% to GBP16.7 million from GBP13.8 million a year ago, "despite the continued absence of meaningful travel-related activity". "The hard work undertaken on both product development and cost restructuring over the last twelve months has really paid off as can be seen from these excellent revenues for [the second half of] 2021. Given the growth trajectory, we remain highly confident about the revenue prospects for second half of the year," says CEO Ian Taylor.

----------

ReNeuron Group PLC - Pencoed, Wales-based developer of cell-based therapeutics - Posts pretax loss for the year to end March of GBP13.4 million, narrowing from GBP13.9 million. Revenue falls sharply to GBP257,000 from GBP6.1 million. Revenue mostly comes from royalties from non-therapeutic licensing activities and income from research collaboration activities. Research development costs fall 41% to GBP9.5 million from GBP16.3 million. "Our decision in 2020 to focus the Company's resources on our retinal disease programme and our exosome and iPSC platforms has resulted in significantly lower operating costs, as reflected in the results for the year," says CEO Olav Hellebo. Looks forward to "data-driven potential value inflection points" over the next 12 months.

----------

JPMorgan Global Core Real Assets Ltd - real estate, transportation and infrastructure investor - Posts net asset value per share at February 28 of 87.9p, tumbling 9.1% from 96.8p a year ago. Pretax loss widens to GBP12.7 million from GBP4.7 million. Annual payout stands at 3.25p per share. Last year, the firm paid a maiden interim dividend of 0.75p per share. "The directors intend to maintain the current level of dividend payments and review the level of dividend cover in the coming quarter...Your board is hopeful that over the longer term the success of the underlying businesses into which we invest will facilitate a steadily growing level of dividends." says company. Says it has weathered the pandemic and the only headwind is "the current strength of pound sterling relative to most foreign currencies, an issue which many regard as a 'high quality problem'".

----------

Yu Group PLC - Nottingham, England-based supplier of gas, electricity and water to the UK business market - Says it has made a "very strong" start to the year and expects the positive momentum to continue. In the six months to end June, revenue is expected to increase 42% to GBP65.0 million from GBP45.9 million a year ago. Says it is confident it will meet market expectations for the year. Expects to report a strong earnings before interest, tax, depreciation and amortisation performance for the year, with further improvement into 2022 as "the group benefits from high scale benefits and its digital roll out".

----------

Mpac Group PLC - Coventry, England-based packaging company - Says the strong momentum in the second half of 2020 has continued into the first half of 2021. In the first half of 2021, order intake has been "significantly above" the Covid-impacted first half of 2020. Says it is comfortable with current full year market expectations. "I am pleased to report a strong start to 2021 across all regions. The outlook is positive based on trends in new prospects and customer investment discussions, and we enter the second half of 2021 with both a strong order book and a developing prospect pipeline and we remain confident that we can leverage the One Mpac operating model to deliver sustainable profitability," says CEO Tony Steels.

----------

InnovaDerma PLC - London-based developer of beauty, personal care and life science products - Says despite Covid-19 headwinds, revenues for the year have performed broadly in line with expectations. Expects revenue for year to end June of no less than GBP10.2 million, down 23% from GBP13.3 million last year. Believes that future prospects will improve once Covid-19 restrictions are lifted and social norms return. Expects to return to profitability for the year to end June 2022.

----------

Surface Transforms PLC - Liverpool-based maker of carbon‐ceramic automotive brake discs - Says revenue in first half of 2021 grows 34% to GBP1.2 million from GBP900,000 a year prior, exceeding managements' original expectations. Says revenue is expected to increase further in the final quarter of 2021 following the start of production on the multi-year original equipment manufacturing contracts.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.